John H Robinson Selected Research

Cutaneous anthrax

1/2015	Natural cutaneous anthrax infection, but not vaccination, induces a CD4(+) T cell response involving diverse cytokines.
5/2014	Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.
4/2010	Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John H Robinson Research Topics

Disease

10	Rheumatoid Arthritis 04/2016 - 01/2006
8	Arthritis (Polyarthritis) 04/2016 - 02/2006
7	Infections 01/2015 - 09/2002
4	Experimental Arthritis 01/2013 - 05/2007
3	Anthrax 01/2015 - 04/2010
3	Cutaneous anthrax 01/2015 - 04/2010
3	Plague (Bubonic Plague) 10/2010 - 09/2006
1	Fibrosis (Cirrhosis) 12/2015
1	Liver Diseases (Liver Disease) 12/2015
1	Cystic Fibrosis (Mucoviscidosis) 12/2014
1	Melioidosis 12/2014
1	Autoimmune Diseases (Autoimmune Disease) 05/2014
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 05/2013
1	Chondrosarcoma 05/2013
1	Femoral Neck Fractures 05/2013
1	Melanoma (Melanoma, Malignant) 05/2013
1	Osteoarthritis 05/2013
1	Bacterial Infections (Bacterial Infection) 04/2010
1	Ankylosing Spondylitis 01/2009
1	Bartonella Infections (Bartonellosis) 10/2008
1	Inflammation (Inflammations) 02/2005
1	Septic Shock (Toxic Shock Syndrome) 01/2002
1	Foodborne Diseases 01/2002
1	Staphylococcal Infections 01/2002

Drug/Important Bio-Agent (IBA)

9	EpitopesIBA 01/2015 - 02/2006
8	AntigensIBA 01/2015 - 01/2006
6	AutoantigensIBA 04/2016 - 02/2006
6	VaccinesIBA 01/2015 - 09/2002
5	Proteoglycans (Proteoglycan)IBA 04/2016 - 01/2009
5	Peptides (Polypeptides)IBA 04/2016 - 02/2005
5	Aggrecans (Aggrecan)IBA 05/2014 - 01/2009
4	Proteins (Proteins, Gene)FDA Link 04/2016 - 09/2006
4	Collagen Type II (Type II Collagen)IBA 12/2010 - 02/2006
2	CytokinesIBA 01/2015 - 01/2013
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 12/2014 - 04/2010
2	Subunit VaccinesIBA 05/2014 - 12/2006
2	Immunodominant EpitopesIBA 05/2014 - 10/2010
2	Freund's AdjuvantIBA 01/2013 - 05/2007
2	Therapeutic UsesIBA 09/2011 - 12/2010
1	Deubiquitinating EnzymesIBA 12/2015
1	LDN 57444IBA 12/2015
1	Ubiquitin Thiolesterase (Ubiquitin Carboxy-Terminal Hydrolase)IBA 12/2015
1	Interleukin-5 (Interleukin 5)IBA 01/2015
1	anthrax toxin (anthrax lethal factor)IBA 01/2015
1	FlagellinIBA 12/2014
1	Bos taurus structural-GP proteinIBA 05/2014
1	AntibodiesIBA 05/2014
1	Poly I-CIBA 05/2013
1	RNA (Ribonucleic Acid)IBA 05/2013
1	Double-Stranded RNA (RNA, Double Stranded)IBA 05/2013
1	Messenger RNA (mRNA)IBA 05/2013
1	Pattern Recognition ReceptorsIBA 05/2013
1	Matrix Metalloproteinase 13IBA 05/2013
1	ammonium bromideIBA 01/2013
1	bis(p-chlorophenyl)acetic acid (DDA)IBA 01/2013
1	Combined VaccinesIBA 10/2010
1	Anthrax Vaccines (Vaccines, Anthrax)IBA 04/2010
1	Anti-Bacterial Agents (Antibiotics)IBA 04/2010
1	isinglassIBA 10/2008
1	Histocompatibility Antigens Class IIIBA 05/2007
1	HLA-DR1 Antigen (HLA DR1 Antigen)IBA 05/2007
1	NADPH Oxidases (NAD(P)H oxidase)IBA 09/2004
1	N- succinimidyl- 5- iodo- 3- pyridinecarboxylic acidIBA 09/2002
1	staphylococcal enterotoxin BIBA 01/2002
1	SuperantigensIBA 01/2002

Therapy/Procedure

2	Therapeutics 09/2011 - 01/2009
1	Ligation 12/2015
1	Aftercare (After-Treatment) 12/2010
1	Intravenous Injections 12/2010
1	Immunotherapy 01/2006